Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).

Johnson & Johnson โปรไฟล์



สัญลักษณ์ย่อของหุ้นJNJ

ชื่อบริษัทJohnson & Johnson

วันที่เสนอขายครั้งแรกOct 31, 2080

ซีอีโอDuato (Joaquin Boix)

จำนวนพนักงาน138100

ประเภทการรักษาความปลอดภัยOrdinary Share

สิ้นปีงบประมาณOct 31

ที่อยู่One Johnson & Johnson Plaza

เมืองNEW BRUNSWICK

ตลาดหลักทรัพย์NASDAQ OMX NASDAQ Basic NYSE

ประเทศUnited States of America

รหัสไปรษณีย์08933

โทรศัพท์17325242455

เว็บไซต์https://www.jnj.com/

สัญลักษณ์ย่อของหุ้นJNJ

วันที่เสนอขายครั้งแรกOct 31, 2080

ซีอีโอDuato (Joaquin Boix)

ผู้บริหารบริษัทของ Johnson & Johnson



ชื่อ

ชื่อ/ตำแหน่ง

ตำแหน่ง

การถือหุ้น

เปลี่ยน

Mr. Joaquin Boix Duato

Chairman of the Board, Chief Executive Officer

307.82K

-15.75%

Ms. Jennifer L. Taubert

Executive Vice President, Worldwide Chairman, Innovative Medicine

194.45K

+8.45%

Ms. Kathryn E. Wengel

Executive Vice President, Chief Technical Operations & Risk Officer

114.63K

Mr. Joseph J. Wolk

Chief Financial Officer, Executive Vice President

85.01K

+0.07%

Prof. Dr. John C. Reed, M.D., Ph.D.

Executive Vice President - Innovative Medicine, Research and Development

24.91K

+57.22%

Ms. Vanessa Broadhurst

Executive Vice President - Global Corporate Affairs

23.00K

Ms. Kristen Mulholland

Executive Vice President, Chief Human Resources Officer

19.83K

+28.80%

Ms. Elizabeth (Liz) Forminard

Executive Vice President, Chief Legal Officer

16.99K

-38.68%

Mr. Hubert Joly

Independent Director

5.00K

Ms. Marillyn A. Hewson

Lead Independent Director

3.00K

ดูเพิ่มเติม